What does Elucid make?

AI software that analyses coronary and carotid CT angiography scans: Plaque-IQ for plaque measurement and FFR-IQ for noninvasive fractional flow reserve estimates.

When was Elucid FFR-IQ cleared by the FDA?

The FDA cleared FFR-IQ under 510(k) number K262015 on 29 September 2026. Elucid announced it on 21 October 2026.

TechAILatest.newsTrackers

Medical imaging AI company

Elucid

Elucid is a Boston medical technology company that builds AI software for coronary and carotid CT angiography. Its Plaque-IQ software measures and characterises atherosclerotic plaque, and FFR-IQ, cleared by the FDA in September 2026, estimates fractional flow reserve from the same scan to judge whether a narrowed artery limits blood flow.

Last reviewed 28 Oct 2026

Facts at a glance

Type	Medical imaging software company
Headquarters	Boston, Massachusetts, United States
Products	Plaque-IQ (CT plaque analysis), FFR-IQ (FFR-CT) source
CEO	Kelly Huang, PhD source
FFR-IQ FDA clearance	510(k) K262015, decision dated 29 September 2026 source
FFR-IQ study result	92.2% sensitivity, 93.1% specificity in the ELUCIDATE FFR-CT study, Elucid says source

Questions people ask

What does Elucid make?: AI software that analyses coronary and carotid CT angiography scans: Plaque-IQ for plaque measurement and FFR-IQ for noninvasive fractional flow reserve estimates.
When was Elucid FFR-IQ cleared by the FDA?: The FDA cleared FFR-IQ under 510(k) number K262015 on 29 September 2026. Elucid announced it on 21 October 2026.